Intersect ENT (NSDQ:XENT) shares jumped yesterday 11% to reach a peak of $13.20 apiece after the company released its preliminary financial results for the 4th quarter, narrowly beating analysts’ expectations on Wall Street.
The Menlo Park, Calif.-based company said it expects a total revenue of $24.o – $24.2 million for Q4, slightly ahead of the consensus on The Street, where analysts were looking for sales of $23.1 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT shares jump on Q4 prelims appeared first on MassDevice.